ReviewWorld journal of gastroenterology2025
Translational artificial intelligence in gastrointestinal and hepatic disorders: Advancing intelligent clinical decision-making for diagnosis, treatment, and prognosis.
Review in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reprogramming the gastrointestinal microenvironment with intelligent biomaterials and digital medicine: a perspective on precision intervention for digestive diseases.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal and hepatic disorders exhibit significant heterogeneity, characterized by complex and diverse clinical phenotypes. Most lesions present without typical symptoms in their early stages, which poses substantial challenges for early clinical identification and intervention. As an interdisciplinary field at the forefront of technology, artificial intelligence (AI) integrates theoretical innovation, algorithm development, and engineering applications, triggering paradigm shifts within the medical field. Current research trends indicate that AI technology is progressively permeating the entire diagnostic and therapeutic process for gastrointestinal and hepatic disorders, facilitating intelligent transformations in precise lesion detection, optimization of treatment decisions, and prognosis evaluation through the integration of different modal data, construction of intelligent algorithms, and establishment of clinical verification systems. This article systematically reviews the latest advancements in AI technology concerning the diagnosis and treatment of gastrointestinal diseases (such as inflammatory bowel disease and digestive system tumors) and hepatic diseases (including hepato-cirrhosis and liver cancer), emphasizing its application value and transformative potential in critical areas such as imaging omics analysis, endoscopic intelligent identification, and personalized treatment prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.